Stock Price & Analysis

TWST

0.000

0.000(0%)6M

TWST Stock Price Chart

YTD

TWST Key Stats

High

43.570

Vol

1.32M

Low

40.500

Amount

56.28M

Open

41.860

VWAP

42.64

Mkt Cap

2.56B

TWST Company Profile

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. It has miniaturized traditional chemical DNA synthesis reactions to write over one million short pieces of DNA on each silicon chip. It offers two product lines: synthetic biology tools and NGS tools, that address different needs of its customers across a variety of applications. It offers ribonucleic acid and protein products. Its synthetic biology products include synthetic genes and gene fragments, and oligonucleotide or oligo pools.

TWST Technical Analysis

Instant technical analysis with one click on any asset

TWST Why It Moves

Find out the reasons behind the current stock movement

Should I Buy TWST

AI-powered analysis to guide your buy, sell, or hold decision for this stock

TWST News Sentiment

AI uncovers potential trading opportunities based on news sentiment

TWST Technical Analysis

Instant technical analysis with one click on any asset

TWST Why It Moves

Find out the reasons behind the current stock movement

Should I Buy TWST

AI-powered analysis to guide your buy, sell, or hold decision for this stock

TWST News Sentiment

AI uncovers potential trading opportunities based on news sentiment

TWST Fundamental Analysis

buy

Moderate Buy

Buy

Hold

Sell

High

62.00

Averages

54.29

Low

40.00

Analyst

Rating

Action

Price Target

Date

Rating Reason

Baird

Catherine Ramsey

Buy

Maintains

$48 → $54

2025-02-04

JP Morgan

Rachel Vatnsdal

Sell

Maintains

$35 → $40

2025-02-04

Scotiabank

Sung Ji Nam

Buy

Maintains

$54 → $62

2025-02-04

Wolfe Research

Doug Schenkel

Buy

Initiates

$60

2024-12-13

Wolfe

TD Cowen

Steven Mah

Strong Buy

Reiterates

$58

2024-11-26

Sees

Analyst	Rating	Action	Price Target	Date	Rating Reason

Baird Catherine Ramsey	Buy	Maintains	$48 → $54	2025-02-04
JP Morgan Rachel Vatnsdal	Sell	Maintains	$35 → $40	2025-02-04
Scotiabank Sung Ji Nam	Buy	Maintains	$54 → $62	2025-02-04
Wolfe Research Doug Schenkel	Buy	Initiates	$60	2024-12-13	Wolfe
TD Cowen Steven Mah	Strong Buy	Reiterates	$58	2024-11-26	Sees

TWST Earnings Analysis

Twist Bioscience Corporation Common Stock Corporation (TWST.O) Q4 2024 Earnings Conference Call

Positive

Record Revenue and Margin Growth: Twist delivered record quarterly revenue and margin growth, ending the year with a strong cash balance.
Performance Exceeds Guidance: We exceeded our guidance in every metric, including total revenue, gross margin, capital expenditure and ending cash balance.
Consistent Revenue Increase: We increased revenue for the seventh quarter in a row, reporting $84.7 million, an increase of 27% year-over-year and 4% sequentially.
Revenue Increase of 28%: For the year, we reported $330 million in revenue, an increase of 28% over fiscal 2023.
Quarterly Gross Margin Performance: Gross margin for the quarter came in ahead of our guidance at 45.1%.

Negative

Adjusted EBITDA Improvement: For fiscal 2024, adjusted EBITDA was a loss of approximately $93.5 million, an improvement of approximately $54 million versus $147.3 million for fiscal 2023.
Operating Cash Flow Comparison: Net cash used in operating activities was $64.1 million compared to $142.5 million for the equivalent 12-month period in 2023.
Operating Expenses Comparison: Operating expenses, excluding cost of revenues for fiscal 2024 were $354 million, including the impairment charge of $45 million in fiscal Q3, compared with $307 million in fiscal 2023.
Gross Margin Improvement Outlook: We expect to see continued improvement in gross margins sequentially throughout the year, but the timing of which is a bit uncertain on some of when they'll actually hit the P&L.
Adjusted EBITDA Loss Forecast: We expect adjusted EBITDA losses of approximately $60 million to $65 million for fiscal 2025, an improvement of approximately $30 million to $35 million versus fiscal 2024.

Positive

Record Revenue and Margin Growth: Twist delivered record quarterly revenue and margin growth, ending the year with a strong cash balance.
Performance Exceeds Guidance: We exceeded our guidance in every metric, including total revenue, gross margin, capital expenditure and ending cash balance.
Consistent Revenue Increase: We increased revenue for the seventh quarter in a row, reporting $84.7 million, an increase of 27% year-over-year and 4% sequentially.
Revenue Increase of 28%: For the year, we reported $330 million in revenue, an increase of 28% over fiscal 2023.
Quarterly Gross Margin Performance: Gross margin for the quarter came in ahead of our guidance at 45.1%.

Negative

Adjusted EBITDA Improvement: For fiscal 2024, adjusted EBITDA was a loss of approximately $93.5 million, an improvement of approximately $54 million versus $147.3 million for fiscal 2023.
Operating Cash Flow Comparison: Net cash used in operating activities was $64.1 million compared to $142.5 million for the equivalent 12-month period in 2023.
Operating Expenses Comparison: Operating expenses, excluding cost of revenues for fiscal 2024 were $354 million, including the impairment charge of $45 million in fiscal Q3, compared with $307 million in fiscal 2023.
Gross Margin Improvement Outlook: We expect to see continued improvement in gross margins sequentially throughout the year, but the timing of which is a bit uncertain on some of when they'll actually hit the P&L.
Adjusted EBITDA Loss Forecast: We expect adjusted EBITDA losses of approximately $60 million to $65 million for fiscal 2025, an improvement of approximately $30 million to $35 million versus fiscal 2024.

TWST News

5.0

03-11Newsfilter

Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost

5.0

03-01Benzinga

Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday

5.0

02-15Benzinga

Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday

4.5

02-11NASDAQ.COM

Notable Two Hundred Day Moving Average Cross - TWST

5.0

02-11Benzinga

Cathie Wood Dumps $16 Million Worth Of Palantir Stock After Record Highs

TWST FAQs

Should I buy or sell TWST Stock?

Analysis and Insights

To determine whether to buy or sell TWST stock, we analyze both technical and fundamental factors:

Technical Analysis:

TWST's stock price has been experiencing volatility, with a recent decline in price. The stock is currently trading near its lower Bollinger Band, suggesting potential oversold conditions. The MACD indicator shows a bearish signal, and the RSI is around 50, indicating a neutral position.

Fundamental Analysis:

Ark Invest's recent purchase of TWST shares in February 2025 indicates confidence, but their subsequent sale may signal profit-taking. Analyst sentiment is mixed, with Baird maintaining a Buy rating and JP Morgan advising to Sell. The stock's valuation metrics and recent price movements suggest uncertainty.

Analyst Sentiment:

Analysts are divided, with some expecting growth and others cautioning against potential declines. The mixed ratings reflect the stock's uncertain outlook.

Conclusion:

Given the mixed analyst sentiment, recent price decline, and bearish technical indicators, it may be prudent to hold or wait for further positive developments before deciding to buy.